These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 26238598)

  • 21. Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases.
    Raman S; Ding K; Chow E; Meyer RM; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JSY; Nabid A; Haas R; Wiggenraad R; Babington S; Demas WF; Wilson CF; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2018 Apr; 27(4):1089-1098. PubMed ID: 29188483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
    Meltzer HY; Risinger R; Nasrallah HA; Du Y; Zummo J; Corey L; Bose A; Stankovic S; Silverman BL; Ehrich EW
    J Clin Psychiatry; 2015 Aug; 76(8):1085-90. PubMed ID: 26114240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 24. Defining the Minimal Clinically Important Difference for Patients With Vestibular Schwannoma: Are all Quality-of-Life Scores Significant?
    Kerezoudis P; Yost KJ; Tombers NM; Celda MP; Carlson ML; Link MJ
    Neurosurgery; 2019 Dec; 85(6):779-785. PubMed ID: 30395303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Wisconsin gait scale - The minimal clinically important difference.
    Guzik A; Drużbicki M; Wolan-Nieroda A; Przysada G; Kwolek A
    Gait Posture; 2019 Feb; 68():453-457. PubMed ID: 30599331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the minimum clinically important difference in quality of life in schizophrenia measured by the Quality of Well-Being Scale and disease-specific measures.
    Thwin SS; Hermes E; Lew R; Barnett P; Liang M; Valley D; Rosenheck R
    Psychiatry Res; 2013 Oct; 209(3):291-6. PubMed ID: 23473656
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach.
    Duru G; Fantino B
    Curr Med Res Opin; 2008 May; 24(5):1329-35. PubMed ID: 18377706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
    Stacy M; Sajatovic M; Kane JM; Cutler AJ; Liang GS; O'Brien CF; Correll CU
    Mov Disord; 2019 Aug; 34(8):1203-1209. PubMed ID: 31234240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal clinically important differences in the EORTC QLQ-BM22 and EORTC QLQ-C15-PAL modules in patients with bone metastases undergoing palliative radiotherapy.
    Raman S; Ding K; Chow E; Meyer RM; Nabid A; Chabot P; Coulombe G; Ahmed S; Kuk J; Dar AR; Mahmud A; Fairchild A; Wilson CF; Wu JSY; Dennis K; DeAngelis C; Wong RKS; Zhu L; Brundage M
    Qual Life Res; 2016 Oct; 25(10):2535-2541. PubMed ID: 27138964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.
    Ascher-Svanum H; Novick D; Haro JM; Aguado J; Cui Z
    Qual Life Res; 2013 Oct; 22(8):2085-94. PubMed ID: 23239123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation of an abbreviated quality of life scale for schizophrenia.
    Fervaha G; Remington G
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1072-7. PubMed ID: 23235268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obtaining employment as an anchor for estimating the minimum clinically important difference on the Positive and Negative Syndrome Scale (PANSS) in schizophrenia.
    Leddy-Stacy MA; Rosenheck R
    Psychiatry Res; 2016 Apr; 238():304-309. PubMed ID: 27086249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with adherence to treatment with olanzapine and other atypical antipsychotic medications in patients with schizophrenia.
    Liu-Seifert H; Osuntokun OO; Feldman PD
    Compr Psychiatry; 2012 Jan; 53(1):107-15. PubMed ID: 21310400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response and remission rates with adjunctive aripiprazole in patients with major depressive disorder who exhibit minimal or no improvement on antidepressant monotherapy.
    Casey DE; Laubmeier KK; Eudicone JM; Marcus R; Berman RM; Rahman Z; Sheehan J
    Int J Clin Pract; 2014 Nov; 68(11):1301-8. PubMed ID: 25196314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of symptomatology and cognitive deficits to functional capacity in schizophrenia.
    Perlick DA; Rosenheck RA; Kaczynski R; Bingham S; Collins J
    Schizophr Res; 2008 Feb; 99(1-3):192-9. PubMed ID: 17851042
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
    Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W
    Schizophr Res; 2007 Mar; 91(1-3):178-86. PubMed ID: 17303388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life and cognitive dysfunction in people with schizophrenia.
    Ueoka Y; Tomotake M; Tanaka T; Kaneda Y; Taniguchi K; Nakataki M; Numata S; Tayoshi S; Yamauchi K; Sumitani S; Ohmori T; Ueno S; Ohmori T
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):53-9. PubMed ID: 20804809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?
    Beasley CM; Sutton VK; Taylor CC; Sethuraman G; Dossenbach M; Naber D
    J Clin Psychopharmacol; 2006 Feb; 26(1):40-4. PubMed ID: 16415704
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Defining the minimum clinically important difference for grade I degenerative lumbar spondylolisthesis: insights from the Quality Outcomes Database.
    Asher AL; Kerezoudis P; Mummaneni PV; Bisson EF; Glassman SD; Foley KT; Slotkin JR; Potts EA; Shaffrey ME; Shaffrey CI; Coric D; Knightly JJ; Park P; Fu KM; Devin CJ; Archer KR; Chotai S; Chan AK; Virk MS; Bydon M
    Neurosurg Focus; 2018 Jan; 44(1):E2. PubMed ID: 29290132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minimal Clinically Important Difference for PROMIS Physical Function in Patients With Distal Radius Fractures.
    Sandvall B; Okoroafor UC; Gerull W; Guattery J; Calfee RP
    J Hand Surg Am; 2019 Jun; 44(6):454-459.e1. PubMed ID: 30954311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.